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Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disease that affects
motor neurons of the brain and spinal cord. Many studies indicate that mitochondrial
oxidative stress (MOS) is a principal mechanism underlying the pathophysiology of this
and other devastating neurodegenerative diseases. Here, we investigated a unique whey
protein supplement (Immunocal®) to determine its neuroprotective efficacy in several in
vitro models of MOS and in an in vivo mouse model of ALS. This non-denatured whey
supplement contains cystine which is an oxidized form of cysteine, an essential precursor
for synthesis of the endogenous antioxidant, glutathione (GSH). In primary cultured rat
cerebellar granule neurons (CGNs), pre-incubation with Immunocal® completely
protected against MOS induced by HA14-1, an inhibitor of the pro-survival Bcl-2
protein. This effect was prevented by co-incubation with the gamma-glutamyl cysteine
ligase inhibitor, buthionine sulfoximine, demonstrating that the de novo synthesis of
GSH underlies the neuroprotective mechanism of Immunocal®. Additionally,
Immunocal® displayed significant protection against an array of MOS-inducing agents,
including sodium nitroprusside, copper, and aluminum, supporting its ability to
upregulate mitochondrial antioxidant capacity. In accordance with these findings in
CGNs, Immunocal® decreased cell death due to both H2O2 and glutamate toxicity in
NSC34 motor neuron-like cells. Immunocal® also significantly protected CHO cells
ii

from MOS evoked by overexpression of amyloid precursor protein (APP). Immunocal®
treatment in NSC34 motor neuron-like cells decreased cell death caused by both H2O2
and glutamate glycine. Most compelling are our findings in the hSOD1G93A mouse model
of ALS. These mice were given Immunocal® (3.33% solution in drinking water) ad
libitum, beginning at 60-days-old. Although no effect on overall survival was observed,
Immunocal®-treated mice displayed a significant (7 ±1.08 day) delay in disease onset,
compared to mutant control mice. Importantly, Immunocal®-treated mice showed a
highly significant decrease in the rate of decline in grip strength. Finally, using HPLCECD we found that whole blood and lumbar spinal cord GSH levels were each depleted
by nearly 50% in end-stage hSOD1G93A mice, and these reductions were essentially
prevented in mutant mice receiving Immunocal®. These findings suggest that sustaining
GSH by supplementation with Immunocal® may help to mitigate the progression of ALS
through suppression of MOS. In addition to investigating Immunocal® for its
neuroprotective efficacy, we also show that an anthocyanin-enriched fraction from
strawberries delays disease onset and extends survival in the hSOD1G93A mouse model of
ALS. These cumulative data suggest that nutraceutical antioxidants hold promise in
neurodegenerative disease.
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Chapter 1: Introduction
1.1. Oxidative stress and neurodegenerative disease

Mitochondrial oxidative stress (MOS) and dysfunction are major factors
underlying the pathophysiology of several devastating neurodegenerative disorders
including Parkinson’s disease (PD), Alzheimer’s disease (AD), and amyotrophic
lateral sclerosis (ALS) [1]. Reactive oxygen species (ROS) are generated in
substantial quantities during normal cell metabolism, in particular, at the level of
mitochondria as a byproduct of electron transport and ATP production. ROS can play
essential roles in cell signaling; however, when these free radicals are produced in
excess of antioxidant defense mechanisms, cell damage and death will follow [2,3].
The brain is especially vulnerable to oxidative damage because of its high lipid
content and high rate of oxygen consumption. As a result of oxidative damage,
region-specific neuronal cell death is an underlying cause of each of the abovementioned neurodegenerative diseases [4].
There is mounting evidence suggesting that deficiencies in the electron transport
chain (ETC) and subsequent oxidative stress at the level of the mitochondria are
integral factors in a variety of neurodegenerative diseases [5,6]. ETC deficits lead to
decreased ATP production and increases in ROS [7]. More specifically, oxidative
damage causes complex I deficiencies in the ETC and further increases ROS
1

production in PD [8]. For instance, complex I deficiency and the consequent increase
in mitochondrial ROS play a critical role in the death of dopaminergic neurons in PD
[9]. Consistent with this concept, mice heterozygous for deletion of the
mitochondrial-specific, manganese-superoxide dismutase (SOD2) gene show
markedly increased susceptibility to dopaminergic neuronal loss induced by the
complex I inhibitor, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine [10].
Pathophysiologically relevant complex I inhibitors such as rotenone and Nmethylpyridinium ion (MPP+) generate free radicals and induce dopaminergic
pathology which is used to model PD in vitro and in vivo for studies into potential
therapeutics [11,12]. Methods aimed at bolstering endogenous antioxidant defense
mechanisms to scavenge free radicals generated by these toxic compounds during
disease progression hold therapeutic potential for neurodegenerative diseases such as
PD.
Additionally, amyloid-β precursor protein (AβPP) aggregates, which are a
pathological hallmark in AD, have been shown to induce MOS and cytochrome c
release in vitro and in vivo [13,14]. Aβ accumulation and oligomerization has been
proposed to lead to mitochondrial dysfunction and caspase activation [15]. In either
patients with AD or mutant AβPP transgenic mice, beta-amyloid associates with the
mitochondrial Aβ-binding alcohol dehydrogenase (ABAD) and triggers an enhanced
generation of mitochondrial ROS [16]. Moreover, overexpression of ABAD in mutant
AβPP expressing mice increases neuronal oxidative stress and worsens spatial
memory deficits. Conversely, crossing of Tg19959 mutant AβPP transgenic mice
2

with mice overexpressing SOD2 significantly reduces amyloid plaque burden and
sustains spatial memory relative to Tg19959 control mice [17]. Healthy and
functional mitochondria are imperative for defense against Aβ-induced oxidative
stress; therefore, therapies that enhance intrinsic antioxidant activity have promise for
this particular neurodegenerative disease [18]. More specifically, strategies that
protect cells at the level of the mitochondria appear to have protective potential in
these diseases [19].
1.2. GSH is a key endogenous antioxidant

One of the crucial modulators of cell survival, under both normal and pathological
conditions, is the endogenous tri-peptide glutathione (GSH, γ-glutamyl-L-cysteinylglycine). GSH is involved in many essential cell processes including DNA synthesis
and cell metabolism, but its primary function is to act as an antioxidant and scavenger
of ROS [20]. GSH exists in a reduced and active state and is oxidized to glutathione
disulfide (GSSG) upon reducing unstable molecules, such as ROS. The reduction of
ROS by GSH is facilitated by the enzyme GSH peroxidase (GPx) [21]. The enzyme,
glutathione reductase (GR), then returns GSSG to its reduced form GSH (Fig. 1) [22].

3

Figure 1. Glutathione metabolism.

Biosynthesis of GSH happens in two distinct steps. The first occurs when γglutamylcysteine ligase (GCL) combines glutamate and cysteine together. This
reaction is the rate-limiting step in GSH synthesis. The second step in GSH synthesis
occurs when GSH synthetase adds glycine to the C-terminus of the end product of the
first step, γ-glutamylcysteine. Cysteine is the rate-limiting precursor in GSH synthesis
(Fig. 2) [22-24]. Because of its potent antioxidant activity, and its neuroprotective
capacity demonstrated in many in vitro and in vivo systems (discussed below),
strategies that enhance GSH synthesis have drawn attention as potentially novel
therapies for neurodegenerative diseases [reviewed in 25].
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Figure 2. Glutathione synthesis.

1.3. Neuroprotective effects of GSH and GSH precursors in vitro and in vivo

Several strategies to increase levels of endogenous GSH have previously shown
to be effective in disease treatment in vitro and in vivo. N-acetylcysteine (NAC)
supplementation provides cysteine in a cell-permeable and non-toxic form, and has
been studied for its efficacy in various neurodegenerative and progressive human
diseases [26-28]. NAC supplementation decreased ROS levels and increased cell
antioxidant potential against rotenone-induced apoptosis in vitro and in a rat model of
PD in vivo. Cell survival was significantly increased in NAC-treated cells and
animals in these models of PD, suggesting that NAC reduced toxicity with its ability
to decrease oxidation of cellular GSH and subsequently decrease ROS [29]. NAC
treatment in SHSY5Y cells has also been shown to decrease levels of Aβ 1-42, and to
5

decrease the levels of phospho-tau protein, which are hallmarks in AD [30]. Finally,
NAC has been investigated in a model of ALS, where it delayed clinical onset and
prolonged survival in hSOD1G93A mice, a familial model of ALS [31].
In addition to NAC, other means of increasing GSH levels have been investigated
for prevention and treatment of various neurodegenerative diseases, though the
research is not as comprehensive as with NAC. Glutathione monoethylester (GSHMEE) is a cell permeable derivative of GSH. Its efficacy has been investigated in
several murine models of neurodegeneration. GSH-MEE has been shown to prevent
mitochondrial GSH depletion and to provide neuroprotection following transient
focal cerebral ischemia [32,33]. Additionally, GSH-MEE has been shown to improve
recovery and survival of spinal cord neurons in a model of spinal cord injury in rats
[34]. These approaches, among other methods of increasing intracellular GSH, are
unique and deserve further investigation in the lab and in the clinic.
1.4. GSH depletion plays a central role in ALS pathogenesis

ALS is the most common adult-onset motor neuron disease. It is characterized
clinically by progressive muscle weakness and atrophy, ultimately leading to
respiratory failure and death, typically within 1 to 5 years of diagnosis. There is
currently only one FDA approved drug for ALS, riluzole, which is an antiglutamatergic compound that merely prolongs survival by 2 to 3 months and has little
effect on quality of life for ALS patients [35,36]. ALS is characterized pathologically
by a progressive loss of motor neurons in the cortex, brainstem, and spinal cord [37].
6

Though its underlying cause remains elusive, oxidative damage due to aberrant
production of ROS and associated mitochondrial dysfunction play key roles in motor
neuron death [38,39,40].
In the case of ALS, mutant forms of copper, zinc-superoxide dismutase (SOD1)
which are collectively responsible for approximately 20% of cases of familial ALS,
accumulate at mitochondria and trigger a shift in the redox state of these organelles
[41]. G93A mutant SOD1 displays a gain-of-toxic-function which is characterized by
an increased generation of mitochondrial ROS [42]. Finally, crossing of hSOD1G93A
mutant mice with mice heterozygous for deletion of the SOD2 gene significantly
exacerbates motor neuron pathology and reduces lifespan in this model of familial
ALS, indicating a central role of MOS in disease pathogenesis [43].
Given the key role of MOS in neuronal cell death, identifying the major players
that regulate the mitochondrial oxidant/antioxidant balance is essential to discover
novel therapeutics for neurodegeneration. Glutathione (GSH) is an endogenous
tripeptide antioxidant that plays a central role in preventing MOS and evading
apoptosis [44]. GSH depletion and a decline in antioxidant enzyme activity have been
observed in the erythrocytes of sporadic ALS patients with active disease [45]. This
decrease in antioxidant defense enzyme activity and GSH metabolism has been
correlated directly with the rate of disease progression [46]. Many characteristic
pathological changes observed in ALS may be induced by intracellular GSH
depletion. For example, the protein TAR DNA-binding protein 43 (TDP-43) forms
cytoplasmic inclusions, which is one of the hallmark pathologies seen in sporadic
7

ALS patients. These TDP-43 inclusions can be recapitulated in cultured neurons
subjected to GSH depletion [47]. Oxidative stress also causes accumulation and
aggregation of mutant SOD1 in familial ALS, and these inclusions have been shown
to decrease GSH content, which is attributed to disruption of mitochondrial function
[48,49]. In agreement, SOD1 knockout causes oxidative stress and subsequent distal
motor axonopathy, as well as significant GSH oxidation [50].
The familial ALS-associated mutant, hSOD1G93A, has recently been shown to
have significant effects on mitochondrial GSH in vitro. NSC34 motor neuronal cells
stably expressing hSOD1G93A display a significant and selective decrease in
mitochondrial GSH content when compared to parental NSC34 cells [51].
Furthermore, these NSC34/hSOD1G93A cells demonstrate significantly enhanced
sensitivity to the GSH depleting agent, ethacrynic acid. In a similar manner, infection
of NSC34 cells with adenoviral hSOD1G93A induces oxidative stress, mitochondrial
dysfunction, and intrinsic apoptosis which are significantly alleviated by coexpression of the mitochondrial antioxidant enzymes SOD2 and GSH peroxidase-4
[52]. Finally, NSC34 cells expressing hSOD1G93A but not wild type SOD1, show
marked morphological and functional alterations in mitochondria and exhibit a
significant decrease in the reduced GSH to oxidized GSSG ratio in mitochondria
following exposure to the inflammatory cytokines, tumor necrosis factor alpha and
interferon gamma [53]. Thus, hSOD1G93A appears to sensitize motor neuronal cells to
MOS and apoptosis by specifically diminishing the mitochondrial GSH pool. These
cumulative data suggest a prominent role for GSH depletion in ALS pathogenesis and
8

therefore, there is great interest in developing a method to target this aspect of the
disease for ALS, other neurodegenerative diseases, as well as non-neuronal
progressive human diseases such as heart disease and cancer.

1.5. Nutraceutical modulation of GSH: Pre-clinical and clinical studies with

Immunocal®
Immunocal® is a novel undenatured whey protein supplement designed to
augment the available intracellular GSH pool. Cellular GSH concentrations are highly
dependent on the availability of cysteine, which is the limiting precursor in GSH
synthesis [54,21]. The cysteine precursor, cystine, occurs in high levels in
Immunocal® because the supplement is rich in serum albumin, alpha-lactalbumin,
and lactoferrin. These proteins have a significant number of cystine residues in this
undenatured preparation. In addition, the direct GSH precursor, glutamylcysteine, is
also present in the serum albumin fraction of the supplement. When cystine is
provided in this peptide form, it is readily cleaved and reduced to two cysteine
molecules within the target cell. This is significant, as cysteine supplementation alone
is cytotoxic [55]. Immunocal® was initially developed as a nutritional supplement to
increase immune system function after dietary amino acids were discovered to
increase immune reactivity [56]. It has been investigated in several human diseases,
and it is one of only a handful of nutritional supplements that are included in the
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Physician’s Desk Reference (PDR). Immunocal® is comprised of natural food
protein and is in the FDA category of generally recognized as safe (GRAS) [57].
Immunocal® was initially studied in various animal models or clinical disorders
of immune system deficiency and cancer as an approach to increase the available
GSH pool and increase cellular antioxidant and immune system defenses. Free radical
generation is a key element of carcinogenesis and diets rich in antioxidants are
believed to decrease one’s susceptibility to cancer [58,59]. Consistent with this,
dietary whey protein decreased tumor burden in a mouse model of
dimethylhydrazine-induced colon cancer [60]. Similarly, Immunocal® was shown to
increase apoptosis in an in vitro model of human hepatoma cells by increasing
cytotoxicity of specific chemotherapeutic agents such as baicalein, a flavone used for
its anti-inflammatory and anti-proliferative properties in cancer cells [61]. In addition
to its anti-tumor effects, this undenatured whey protein was shown to reverse weight
loss in lung cancer patients receiving chemotherapy or radiotherapy [62]. Thus,
Immunocal® provides anti-cancer activity while also preserving overall health, and
its method of action may be applicable in many other human pathologies.
Immunocal® was also investigated as a potential antioxidant therapy in human
immunodeficiency virus (HIV) infection [63]. Oxidative stress is a known activator of
HIV replication and based on this, Immunocal® was tested as an approach to
attenuate this stress by increasing intracellular GSH levels. In a small pilot study,
Immunocal® administration over 3 months was shown to elevate blood GSH by 70%
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in HIV-seropositive individuals back to normal values [64]. Moreover, this restorative
effect on blood GSH was associated with parallel increases in bodyweight.
Oxidative stress plays a significant role in muscle weakness. Immunocal®
administration for 3 months was shown to significantly increase muscle power and
work capacity in comparison to individuals that received placebo treatment.
Undenatured whey protein supplementation also significantly increased lymphocyte
GSH levels compared to placebo (36% +/- 11%) [65]. Oxidative stress is also key in
the pathogenesis of cystic fibrosis. It is well accepted that GSH is a major defense in
lung diseases, such as cystic fibrosis, and treatment methods that augment the
available pool of this antioxidant are continually investigated. In cystic fibrosis
patients receiving Immunocal® for 3 months, there was a 46.6% increase in
lymphocyte GSH levels compared to individuals receiving a placebo [66].
This dietary whey protein supplement was also investigated in diseases of aging,
where it extended longevity by 6.3 months in mice that received the supplement late
in life (specifically, over a 3 month period between 17 and 20 months of age). This
lifespan extension in the mouse corresponds to approximately 25 human years.
Although there was little investigation into the specific mechanism behind this effect,
both heart and liver GSH levels were significantly increased in Immunocal®-fed mice
[67]. To date, there has been minimal investigation into the efficacy of Immunocal®
treatment in neurodegenerative diseases; however, with the wide array of human
diseases that show promising results with this dietary supplement, it is encouraging
for other progressive human diseases. Immunocal® holds potential to increase GSH
11

levels in many relevant disorders like neurodegeneration whose underlying pathology
includes oxidative stress.
1.6. Immunocal® patents

Immunocal® has not been patented specifically for use in neurodegenerative
diseases; however, it has been investigated in depth for several other human
pathologies. Immunocal® appears to show beneficial effects in these diseases because
of its capacity to act as a cysteine-donor, resulting in an increase of GSH levels in
treated individuals. Initial studies with this undenatured whey protein isolate were
conducted to investigate its efficacy in immune system deficiency. Immunocal® is
highly effective in bolstering immune function, and was patented because of its
ability to improve active systemic humoral immune response [68]. More recently, it
was patented for use in HIV-seropositive individuals, in which it induces a decrease
in viral load and an increase in immune function in affected individuals [69]. Finally,
Immunocal® was patented as an anti-cancer therapy because of its ability to increase
the efficacy of certain chemotherapy agents, to decrease the oxidative stress
component of cancer, and to increase the body weight of patients who were receiving
chemotherapy back to healthy levels [70]. This dietary supplement provides a unique
approach to increase intracellular GSH levels, and there is much promise for
Immunocal® in the treatment and prevention of neurodegenerative diseases.
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1.7. Therapeutic approaches to modulate GSH in neurodegenerative disease

Based on extensive evidence that oxidative stress is a fundamental aspect of
neurodegeneration, multiple strategies have been proposed to limit free radical
damage to the nervous system. In particular, methods designed to augment
intracellular GSH levels are of great interest, due to the evolving pool of literature
indicating a key role of GSH depletion in neurodegenerative disease [reviewed in 71].
GSH does not penetrate the blood brain barrier (BBB) and therefore, therapies aimed
at indirectly modulating GSH levels have been investigated, including the
introduction of GSH precursors, analogs, and mimetics [72,73]. Other strategies, such
as bolstering the expression of enzymes responsible for increases in GSH synthesis
for example, are also gaining interest.
The NF-E2-related factor 2 (Nrf2) transcription factor regulates the expression of
several prominent antioxidant defense proteins. Cellular GSH levels are dependent
upon Nrf2 translocation into the nucleus to initiate the expression of key GSH
synthesis enzymes including the catalytic and regulatory subunits of γ-glutamyl
cysteine synthase (GCS) [74,75]. Nrf2 activation is therefore an interesting target to
modulate GSH in an effort to decrease neuronal cell death in relevant
neurodegenerative diseases. Several compounds that stimulate Nrf2 nuclear
translocation and the subsequent increases in GSH synthesis have been investigated
and have proven to be neuroprotective in vitro [76,77]. Consistent with these in vitro
studies, Nrf2 overexpression in glial cells and subsequent GSH secretion from
astrocytes increased survival and delayed disease onset in a famial mouse model of
13

ALS [78]. In a similar manner, stimulation of Nrf2-dependent GSH synthesis by
synthetic triterpenoid compounds also delayed disease onset and enhanced survival in
the SOD1G93A mouse model of ALS [79]. These studies suggest that a promising
approach to Nrf2 activation is increasing GSH levels in the nervous system.
Glutamate transporter-associated protein 3-18 (GTRAP3-18) interacts with
excitatory amino acid carrier 1 (EAAC1) at the plasma membrane. EAAC1 is a
neuronal glutamate/cysteine transporter, responsible for regulating intracellular
cysteine levels. It is suggested that GTRAP3-18 plays a dominant negative role in
cysteine transport when it interacts with EAAC1 [80]. Accordingly, GTRAP3-18
deficient mice show increased intracellular GSH levels, and these mice have
demonstrated a decreased sensitivity to oxidative stress and increased cognitive
function [81]. Thus, inhibitors of GTRAP3-18 may be effective inducers of GSH
accumulation in the nervous system.
Another technique to boost cellular GSH that has received attention is direct Nacetyl-L-cysteine (NAC) supplementation. This has been shown to increase the
available cysteine pool and to decrease oxidative damage [82]. Wobbler mice that
display lower motor neuron degeneration have shown reductions in
neurodegeneration and retention of motor function when administered NAC. They
also display increased GSH levels and increased muscle mass [83].
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1.8. Modulation of GSH using Immunocal® as a neuroprotective and therapeutic

strategy for ALS
Although the mitochondrial GSH content in particular, has not been measured in
vivo in spinal cord of the hSOD1G93A mouse, GSH depletion has been observed in the
spinal cord of end-stage mice [84]. Moreover, crossing of hSOD1G93A mice with mice
lacking the glutamate-cysteine ligase modifier subunit significantly accelerated
disease progression [85]. Conversely, a number of strategies that are predicted to
increase GSH, such as supplementation with N-acetyl-L-cysteine or induction of the
Nrf2 transcription factor, demonstrate significant benefits on disease onset,
progression, and survival in this model of familial ALS [31,78,79]. In the current
study, we investigated the neuroprotective effects of a undenatured whey protein
supplement, Immunocal®, in vitro in several models of MOS and in vivo in the
hSOD1G93A mouse model of familial ALS [86].
1.9. Anthocyanins and neurodegeneration

Anthocyanins are a major sub-class of the extensive flavonoid family, and they
are responsible for the distinctive red, blue, and purple pigments in many fruits and
vegetables. Found in widely consumed foods, including berries, purple sweet
potatoes, red rice, and grapes, they exist in relatively high concentrations compared to
other dietary polyphenolic compounds [87]. Anthocyanins display a number of
potential health benefits that warrant their investigation as potential clinical
treatments for several human disorders. Due to their anti-inflammatory and
15

antioxidant properties, these novel nutraceuticals have proven effective in both in
vitro and in vivo models of various chronic human conditions, including
cardiovascular disease, obesity, atherosclerosis, ophthalmologic disorders, and type II
diabetes [88-92].
The polyphenolic and cationic attributes of anthocyanins and their metabolites
activate a variety of cellular responses. Anthocyanins consist of an aglycon
component, or anthocyanidin, and a sugar moiety (glucose, galactose, or arabinose).
This anthocyanin structure is more stable than its aglycon alone, specifically in acidic
environments such as the stomach. The polyphenolic nature of anthocyanins is
principally responsible for their strong antioxidant and free radical scavenging
activities, and their overall metabolic benefits. There are many known anthocyanins
varying in the anthocyanidin skeleton and the complexity of the attached glycoside
(Fig. 3), implicating multiple pathways for absorption [93].
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Figure 3. Structure of common anthocyanins.

Recent bioavailability studies suggest that anthocyanins are absorbed rapidly from
the stomach and small intestine, and they are highly metabolized resulting in very low
to undetectable concentrations of the parent compound being observed in plasma
within only a few hours of consumption [94,95]. The low concentrations of parent
anthocyanins are seemingly paradoxical to the beneficial role displayed by
anthocyanins in vivo. This issue has drawn interest to their specific mechanism of
action, in particular which metabolites of anthocyanins produce their positive health
effects [96,97].
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1.9.1. Intrinsic antioxidant activity
Anthocyanins have a robust antioxidant capacity, which appears to be highly
effective in several models of neurodegenerative disease [98-100]. They have a high
oxygen radical absorption capacity (ORAC) value, which is partially responsible for
this neuroprotective effect [101-102]. More specifically, anthocyanins act as
antioxidants because of their ability to directly scavenge free radicals and to prevent
ROS formation in affected cells. For example, anthocyanins decrease the formation of
ROS in in vitro models of Aβ peptide-induced toxicity, as well as in H2O2 injury
[99,103]. Additionally, using the highly accurate method of electron spin resonance
(ESR) spectroscopy it has been shown that anthocyanins have a high affinity to
scavenge 1,1-diphenyl-2-picrylhydrazyl (DPPH), alkyl, and hydroxyl free radicals,
and that this increases dose-dependently [103].
Anthocyanins activate the antioxidant response element (ARE), which controls
expression of a large array of endogenous antioxidant and phase II detoxification
genes [104]. This effect appears to be via activation of the Nrf2 transcription factor
[103]. In addition, anthocyanins have been shown to enhance the activities of free
radical scavenging enzymes including superoxide dismutase, catalase, and glutathione
peroxidase [105-106]. Finally, levels of the endogenous antioxidant GSH have been
shown to increase with anthocyanin treatment, suggesting that anthocyanins exert
their protective effects in part, via modulation of endogenous antioxidant defenses,
and not exclusively due to their intrinsic antioxidant activity [107].
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1.9.2. Anti-inflammatory properties
Induction of inflammatory gene expression and subsequent production of
interleukins and pro-inflammatory cytokines is a common feature in
neurodegeneration. Methods that target these inflammatory processes may be
beneficial in limiting neuronal apoptosis associated with disease. Anthocyanins
exhibit significant anti-inflammatory properties, as they have been shown to inhibit
various inflammatory biomarkers, including interleukin-8 (IL-8) [101]. In addition to
decreased IL-8 production, pomegranate anthocyanins suppress activation of nuclear
transcription factor kappaB (NFκB), which is responsible for the expression of
several pro-inflammatory genes. They were also shown to inhibit mitogen-activated
protein kinases (MAPKs), c-Jun N-terminal kinase (JNK) and extracellular signalregulated kinase (ERK), which are responsible for the expression of a number of proinflammatory cytokines [108]. Furthermore, cherry and blackberry anthocyanins act
as potent cyclooxygenase-2 (COX-2) inhibitors; COX-2 is an important proinflammatory enzyme involved in the synthesis of prostacyclin [109,110].
Anthocyanins have been shown to inhibit up to 95% of COX activity at high
concentrations (250 μg/mL) [111]. These cumulative data suggest that anthocyanins
may be useful in attenuating inflammatory processes that are associated with
neurodegenerative disease.
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1.9.3. Anti-apoptotic properties
Anthocyanins modulate specific anti-apoptotic pathways to increase survival in
neuronal cells. They have been demonstrated to regulate both caspase-dependent and
caspase-independent cell death pathways [112]. It is mainly by acting on a variety of
signaling proteins that they promote cell survival. Anthocyanins from purple sweet
potato were shown to suppress JNK activity, release of cytochrome c from
mitochondria, and cell apoptosis in D-galactose-treated mice. Additionally, it was
demonstrated that this protective effect was dependent on phosphatidylinositol 3kinase (PI3K) an upstream activator of pro-survival Akt [106,113]. Anthocyanins
have also been shown to increase the expression of pro-survival proteins such as Bcl2 and to decrease levels of the pro-apoptotic protein Bax, effects which play a
significant role in prevention of 6-hydroxydopamine (6-OHDA)-induced toxicity, a
model of PD [114].
1.10. Anthocyanin absorption and blood brain barrier permeability
Intact anthocyanins taken orally are absorbed rapidly into many relevant tissues
[115,116]. There is considerable interest into the mechanism behind this rapid
absorption, as revealing this process could lead to further development of these
nutraceuticals for treatment of many pertinent diseases. It is likely that absorption
initially occurs in the stomach, which accounts for the rapid kinetics of anthocyanins
appearing in plasma [117]. There is accumulating data suggesting that anthocyanin
transport occurs via a bilitranslocase transporter, primarily into the vascular
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endothelium, and subsequently into target tissue [118]. Despite their rapid uptake into
the systemic circulation, the overall bioavilability of anthocyanins is very low due to
their rapid metabolism and excretion principally as glucuronidated, methylated, and
glycosylated species [119].
Anthocyanins are present in brain endothelial cells and in brain parenchymal
tissue of rodents after one treatment, suggesting that they are capable of crossing the
blood brain barrier (BBB) [120]. They are rapidly transported to the brain after
ingestion, and once there they may accumulate to concentrations up to 0.21 nmol/g of
tissue [121]. It is posited that anthocyanins enter the brain in a similar fashion to their
absorption in the stomach and GI tract. There is a bilirubin-binding motif in
bilitranslocase in the CNS, which is likely the transporter involved in transporting
anthocyanins into the CNS [122]. This interaction occurs between the anthocyanin
and the bilitranslocase due to hydrogen bonds and not charge, which provides further
selectivity for this transport mechanism [123]. Although they do penetrate the BBB,
the concentrations of parent anthocyanins detected in brain tissue after oral
administration fall well below the concentrations which display significant
antioxidant and neuroprotective effects in vitro. This finding suggests that metabolites
of anthocyanins may also play significant neuroprotective roles in vivo. Moreover,
the ability of chronic anthocyanin administration to induce accumulation of
anthocyanins in brain has not been studied. Ultimately, there is very little known
about anthocyanin transport, specifically for BBB permeation, or the possible
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accumulation of anthocyanins or their metabolites in brain after chronic oral dosing.
Both of these areas warrant further investigation.
1.11. Anthocyanin metabolites in neurodegeneration
There are several anthocyanin metabolites that show promise for prevention and
treatment in neurodegenerative disease. Anthocyanin metabolites may be responsible
for the high bioactivity of anthocyanin compounds, despite their apparently low
bioavailability. The various identified metabolites are more stable than the whole
anthocyanins in a variety of conditions, which make them more likely candidates as
the bioactive moieties in target tissues [96,97]. Recent research suggests that different
anthocyanin conjugates are found in high concentrations in circulation, including
sulfated, methylated, glucuronidated, and glycosylated conjugates [124].
Protocatechuic acid (PCA) and the anthocyanidin base are common anthocyanin
metabolites (Fig. 4). During metabolism, the anthocyanidin in its aglycone form has a
tendency to stay intact and retain its basic function. From there, conjugates of the
anthocyanin are readily formed [125]. PCA concentrations have been detected up to
eight times higher than the parent anthocyanin in rodent plasma. PCA has also been
shown to remain in target tissues for longer periods of time than the parent
anthocyanins [126].
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Figure 4. Common anthocyanin metabolites.

Significantly, both PCA and the anthocyanidin base provided significant
protection and decrease of ROS formation in SH-SY5Y neuronal cells treated with
H2O2 [127]. Finally, PCA induced the Nrf2 transcription factor in murine
macrophages; whether similar effects would be observed in neuronal or glial cells has
not been investigated [128]. There are relatively few studies into the neuroprotective
properties of isolated anthocyanin metabolites; however, with the pool of data
suggesting their relevant concentrations and accumulation in tissue, it is important to
further investigate their neuroprotective effects both in vitro and in vivo [129].
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1.12. Hypothesis and rationale
Given the recent interesting research involving GSH modulation as a method to
moderate neurodegeneration, we pursued nutraceuticals that could potentially provide
neuroprotection by this mechanism. Nutraceutical intervention is an appealing option
because of the relatively low side effects and high availability for patients; therefore,
we decided to investigate the efficacy of the whey protein supplement, Immunocal®,
which had yet to be studied in models of neurodegeneration. This protein isolate was
interesting due to its high purity and undenatured conformation, yielding a greater
concentration of active cystine that could be converted to cysteine, which is the
limiting precursor in GSH synthesis. We tested its neuroprotective potential both in
vitro, and eventually in vivo in the hSOD1G93A mouse model of ALS.
In addition to our interest in modulating the available GSH pool with
nutraceutical intervention, we investigated natural compounds that could bolster
cellular antioxidant response by different mechanisms. There is an increasing pool of
literature (discussed above) that points to anthocyanins decreasing cellular apoptosis
in disease models. This was novel, as anthocyanins have never been investigated for
their potential in motor neuron disease. These two separate nutraceutical interventions
had the potential to increase cellular antioxidant defenses through different
mechanisms, and they were very appealing as new therapeutic strategies for
neurodegenerative disease.
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1.13. Summary of major findings
Using in vitro and in vivo models of neurodegeneration, we show here that
Immunocal® protected CGNs from various sources of oxidative stress. Immunocal®
decreased cell apoptosis in CGNs treated with the Bcl-2 inhibitor, HA14-1, and this
protective effect was diminished by the inhibitor of de novo GSH synthesis, BSO.
Additionally, Immunocal® treatment rescued CGNs from CuCl2, AlCl3, and sodium
nitroprusside (SNP)- induced apoptosis. Furthermore, Immunocal® decreased active
caspase-3 expression in CHO cells that were transfected with wild type APP.
Immunocal® also decreased cell death caused by both H2O2 and glutamate glycine in
the motor neuron-like cell line, NSC34s. Next, we evaluated its potential benefit in
ALS by administering it to hSOD1G93A mice. Consistent with prior findings, in which
Immunocal® protected neurons in vitro from MOS via a GSH-dependent mechanism,
this supplement also preserved blood and spinal cord GSH levels in end-stage
hSOD1G93A mice, delayed disease onset, and sustained grip strength in this model of
familial ALS.
After isolating an anthocyanin-enriched extract from freeze dried strawberries
(SAE), we tested its efficacy in the hSOD1G93A mouse model of ALS. SAE
administration delayed disease onset, increased lifespan, and sustained grip strength
in this model of familial ALS. In summary, both Immunocal® and SAE displayed
neuroprotective effects, likely due to their different effects on bolstering both
exogenous and endogenous antioxidant defenses.
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Chapter 2: Materials and Methods
2.1. Materials
2-amino-6-bromo-α-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid
ethyl ester (HA14-1), and sodium nitroprusside (SNP) were obtained from
Calbiochem (San Diego, CA). DL-buthionine-sulfoximine (BSO), 4,6-diamidino-2phenylindole (DAPI), Hoescht dye 33258, and a monoclonal antibody against βtubulin were from Sigma Aldrich Co. LLC (St Louis, MO). The polyclonal antibody
for active caspase-3 was from Promega (Madison, WI). Cy3- and FITC-conjugated
secondary antibodies were from Jackson Immunoresearch Laboratories (West Grove,
PA). HPLC-grade methanol, acetonitrile, and ethyl acetate were obtained from Fisher
Scientific (Pittsburg, PA).
2.2. Cell culture, transfection, and treatment
Rat cerebellar granule neurons (CGNs) were isolated as previously described
from 7-day-old Sprague-Dawley rat pups of both sexes [130]. CGNs were seeded on
35-mm diameter plastic dishes coated with poly-L-lysine at an average density of 2.0
x 106 cells/mL in basal modified Eagle’s medium containing 10% fetal bovine serum,
25 mM KCl, 2 mM L-glutamine, and penicillin (100 units/mL)/streptomycin
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(100µg/mL). Cytosine arabinoside (10 µM) was added to the culture medium 24h
after plating. Experiments were performed after 6 days in culture. Immunocal® (3.3%
w/v) was added in serum-free medium for 24h before treatment with the specified cell
insult (i.e., SNP, HA14-1, etc.) for a further 24h. NSC34 motor neuron-like cells were
seeded in a 6-well plate at an approximate density of 1.0 x 106 cells/mL and
maintained in DMEM high glucose medium containing 10% fetal bovine serum, 2
mM L-glutamine, and penicillin (100 units/mL)/ streptomycin (100µg/mL). For
serum withdrawal, NSC34s were maintained in DMEM high glucose medium
containing 1% fetal bovine serum, 2 mM L-glutamine, and penicillin (100 units/mL)/
streptomycin (100µg/mL) for 7 days prior to being seeded in a 6-well plate at an
approximate density of 1.0 x 106 cells/mL and subsequent experimental treatment.
Immunocal® (3.3, 1.6, 1.1 % w/v) was added in culture medium for 24h before
treatment with the specified cell insult (i.e. H2O2, glutamate glycine) in NSC34s. For
transient transfection, CHO cells were seeded in a 6-well plate at an approximate
density of 1.0 x 106 cells/mL and then cultured for 24 hours in Ham’s F12 medium
containing 10% fetal bovine serum, 2 mM L-glutamine, and penicillin (100
units/mL)/ streptomycin (100µg/mL). Lipofection (5 μg DNA, 5 μL lipofectamine)
was performed in serum-free medium for 6h to express vectors encoding DsRedtagged wild type APP or DsRed. Cells were incubated for 24h post-transfection in
either the absence or presence of Immunocal®.
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2.3. Cell viability, lipid peroxidation, and cellular GSH assay
All assays were performed according to commercially available kit instructions.
GSH/GSSG assay kit was purchased from Oxford Biomedical Research (Oxford,
MI). MTT cell viability assay was from BioAssay Systems (Hayward, CA).
Malondialdehyde (MDA) lipid peroxidation assay was obtained from OXIS Research
Inc. (Foster City, CA).
2.4. Immunocytochemistry
After treatment, CGNs were fixed in 4% paraformaldehyde for 1h, washed once
in PBS, and then permeabilized and blocked in 0.2% Triton X-100 and 5% BSA.
Primary antibodies were diluted in 2% BSA and 0.2% Triton X-100 in PBS, and cells
were incubated with primary antibodies for 24h at 4 oC. They were then washed 5
times in PBS and then incubated for 1h with either Cy3- or FITC-conjugated
secondary antibody diluted in 2% BSA and 0.2% Triton with DAPI. The cells were
washed 5 times with PBS before the addition of anti-quench solution (0.1% pphenylenediamine in PBS). Images were captured using a Zeiss Axiovect-200
incerted fluorescence microscope (Stuttgart, Germany).
2.5. Animal model of ALS
FVB-Tg(hSOD1-G93A) mice with the toxic gain of function hSOD1 Gly93 to
Ala mutation (G93A) were obtained from The Jackson Laboratory (Bar Harbor, ME).
The colony was maintained and bred in the animal facility at the University of
Denver. Animal genotyping was done by the third party company, Transnetyx
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(Cordova, TN). Animals of both sexes were included in each group, with an age and
sex-matched non-transgenic FVB (NonTG) mouse as control. Animals receiving
supplementation had ad libitum access to Immunocal® (3.3%) in drinking water
beginning at 60 days old. Animals receiving SAE were administered a 5% solution
via oral gavage twice daily.
2.6. Clinical tests
PaGE (paw grip endurance) test was determined by the latency of the animal’s
hind limbs to detatch from a conventional housing wire cage lid after inversion, and
was recorded as the average of 3 separate attempts. PaGE test was carried out twice
weekly [131]. Animals were weighed every other day starting on day 30. End-stage
was determined by a failure of the animal to right itself to sternum in 20s. Onset was
determined by the appearance of trembling in one or two hind limbs or failure to
extend one hind limb when suspended by the tail. All animal experiments were
performed according to the University of Denver and IACUC approved protocol.
2.7. Tissue processing
Lumbar spinal cord and whole trunk blood were obtained from end-stage
hSOD1G93A or age and sex-matched NonTG mice following isoflurane overdose, and
were immediately frozen in liquid nitrogen (-196 oC). For HPLC-EC analysis, trunk
blood was weighed and 300 µL of HCl was added to the sample and vortexed rapidly.
It was next centrifuged at 10,000 g for 20 minutes at 4 oC. The supernatant was
removed and added to a new tube containing 10% perchloric acid (PCA), which was
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centrifuged for 10 minutes at 10,000 g at 4 oC. A clear supernatant was removed and
filtered. Lumbar spinal cord was weighed and added to 1 mL of 10% PCA and then
vortexed 3 times for 15s each time. The supernatant was removed and filtered. Spinal
cord GSH and GSSG were normalized to protein concentrations which were
determined by a commercially available protein assay kit (BCA, Thermo Scientific,
PA). Samples were analyzed in triplicate and an additional sample was spiked with
GSH and GSSG to verify peak identification.
2.8. High Performance Liquid Chromatography with Electrochemical Detection
(HPLC-ECD)
GSH and GSSG in samples and known standards were separated by reversedphase HPLC on a C18 bonded silica column at 35 oC (3µm, 3 x 150 mm for whole
blood; 3µm, 3 x 250 mm for lumbar spinal cord) from Dionex, Inc. (Sunnyvale, CA).
Analytes were detected using a CoulArray® detector (model 5600A, ESA) on three
coulometric array cells in series; electrochemical detectors were set between 0 and
900 mV at increments of 100 mV. Concentrations were determined with a standard
curve of each identified analyte. Mobile phase consisted of 125 mmol/L Na3PO4 and
1% methanol in water, pH 2.8 [132]. The flow rate was set to 0.4 mL/min for all
samples. CoulArray® software was used for baseline correction and peak analysis.
2.9. Anthocyanin purification and isolation
Freeze dried strawberry powder was homogenized with methanol and HCl
(0.01%) for 1h at 4 °C. The slurry was then filtered through Whatman no. 1 filter
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paper under vacuum filtration at 40 °C. The filtrate was then applied to a Waters®
C18 cartridge, rinsed with water and HCl (0.1%), and ethyl acetate. The final fraction
left on the column was eluted using methanol and HCl (0.01%), and this final fraction
was evaporated at 40 °C and re-suspended in water [133]. To confirm the purity of
the final strawberry anthocyanin fraction, a sample was run on HPLC-UV with an
Agilent model HP1100 series II with multi-wavelength detector (MWD) set to 520
nm (Avondale, PA), using a reversed phase C18 bonded silica column (3µm, 3 x 150
mm) from Dionex, Inc. (Sunnyvale, CA). 100 μL samples were injected and run at a
flow rate of 0.6 mL/min, and the mobile phase consisted of 0.1% TFA in water and
acetonitrile that were mixed as a gradient. The sample was compared to known
anthocyanin standards.
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Figure 5. Summary of anthocyanin purification process.

2.10. Statistical analysis
Each in vitro experiment was performed in duplicate and repeated a minimum of
three times; data are reported as mean ± standard error of the mean. Statistical
significance was analyzed with a one-way analysis of variance (ANOVA) followed
by post hoc Tukey’s test. Survival and onset data were analyzed with Kaplan-Meier
curves and log rank test with an n value of 13 for each treatment group.
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Chapter 3: Results
3.1. Immunocal® preserves cellular GSH and decreases apoptosis in CGNs exposed
to the Bcl-2 inhibitor, HA14-1

Figure 6. Immunocal® preserves cellular GSH and reduces apoptosis in CGNs exposed to the
Bcl-2 inhibitor, HA14-1 A. Representative images of CGNs left untreated (control), treated with
HA14-1 (15 μM), or pre-incubated for 24h with Immunocal® before HA14-1 treatment for a
further 24h. Panels from left to right, pseudocolored dapi, pseudocolored β-tubulin, merged
images showing β-tubulin, (green) and DAPI, (blue). Scale bar, 10 μm. B. Quantification of
apoptosis for 4 independent experiments performed as in A except some cultures were preincubated with 200 μM BSO as well. Apoptotic cells were those with condensed or fragmented
nuclei. Results are shown as mean +/- SEM, n=4. *** indicates p<.001 compared to control, †††
indicates p<.001 compared to HA14-1, ‡‡‡ indicates p<.001 compared to ICAL + HA14-1. C.
CGNs were treated exactly as described in B. Total cellular GSH was measured as described in
Materials and Methods. Data shown represent the percent of control cellular GSH concentration,
mean +/- SEM, n=4. *** indicates p<.001 compared to control, † indicates p<.05 compared to
HA14-1, and ‡‡ indicates p<.01 compared to ICAL + HA14-1. Significant differences were
determined by one way ANOVA with a post hoc Tukey’s test. Abbreviations used: Con, control;
ICAL, Immunocal®; BSO, Buthionine sulfoximine.
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Primary CGNs were initially incubated with Immunocal® for 24h, followed by a
24h exposure to the BH3 mimetic, HA14-1 (15μM) as we have previously reported
[134-136]. HA14-1 induced marked nuclear condensation and microtubule disruption
(Fig. 6A) indicative of apoptosis (Fig. 6B) while also causing significant depletion of
GSH (Fig. 6C). Immunocal® significantly protected CGNs from apoptosis induced
by HA14-1 and significantly preserved GSH levels. To confirm that the mechanism
of protection was due at least in part, to enhanced GSH synthesis, CGNs were cotreated with Immunocal® and the γ-glutamyl cysteine synthetase-inhibitor,
buthionine sulfoximine (BSO), which prevents GSH synthesis [137]. Co-incubation
with Immunocal® and BSO for 24h before HA14-1 treatment completely prevented
any protective effect that Immunocal® alone displayed against HA14-1 (Fig. 6B).
Moreover, the capacity of Immunocal® to preserve cellular GSH levels upon HA14-1
exposure was eliminated by BSO co-treatment (Fig. 6C). These data indicate that
Immunocal® protects CGNs from MOS induced by the inhibition of Bcl-2 via an
enhanced de novo synthesis of GSH.
3.2. Immunocal® protects CGNs from CuCl2-induced oxidative damage and
decreases cellular lipid peroxidation
To further investigate the neuroprotective potential of Immunocal® in
primary neurons, we used copper chloride (CuCl2) as a model of MOS. Copper
overload is associated with free radical-induced fragmentation of mitochondrial
cardiolipin and reduction in mitochondrial dehydrogenase and electron transport
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chain complex activities [138,139]. This transition metal is known to generate
reactive oxygen species (ROS) such as hydrogen peroxide (H2O2) in vitro, and
has been reported in abnormally high concentrations in several neurodegenerative
diseases [140-141]. In addition, a central role for copper in the motor neuron
death underlying ALS has been suggested [142].

Figure 7. Immunocal® decreases CuCl2-induced apoptosis and lipid peroxidation in
CGNs A. Representative images of CGNs left untreated (control), treated with CuCl2 (50 μM), or
pre-incubated with Immunocal® for 24h before CuCl2 treatment for a further 24h.
Immunocytochemistry shows β-tubulin (green), and DAPI (blue). Scale bar, 10 μm. B.
Quantification of apoptosis for 4 independent experiments performed as in A. Results are shown
as mean +/- SEM, n=4. ** indicates p<.01 compared to control, †† indicates p<.01 compared to
CuCl2. C. Cellular lipid peroxidation (malondialdehyde, MDA) was measured as described in
Materials and Methods. Results are shown as mean +/- SEM, n=5. ** indicates p<.01 compared
to control, ††† indicates p<.001 compared to CuCl2. Abbreviations used: Con, control; ICAL,
Immunocal®.
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Fluorescence analysis of the microtubule network revealed robust protection from
this transition metal in CGNs pre-treated with Immunocal® (Fig. 7A). Quantification
of apoptotic cells revealed that there was a significant reduction in CGN apoptosis
with Immunocal® pre-treatment compared to CGNs treated with CuCl2 alone (Fig.
7B). The antioxidant effect of Immunocal® was confirmed with a lipid peroxidation
assay which revealed a significant decrease in malondialdehyde content in CGNs pretreated with Immunocal® (Fig. 7C).
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3.3. Immunocal® protects CGNs exposed to SNP-generated nitric oxide species and
from AlCl3-induced neurotoxicity

Figure 8. Immunocal® preserves CGN viability and protects from apoptosis after
treatment with SNP A. Representative images of CGNs left untreated (control), treated with
SNP (100 μM), or pre-incubated with Immunocal® for 24h before SNP treatment for a further
24h. Immunocytochemistry shows β-tubulin (green), and DAPI (blue). Scale bar, 10 μm. B.
Quantification of apoptosis for 5 independent experiments performed as in A. Results are shown
as mean +/- SEM, n=5. C. MTT cell viability was measured as described in Materials and
Methods. Results are shown as mean +/- SEM, n=3.For B and C, *** indicates p<.001 compared
to control, ††† indicates p<.001 compared to SNP. Abbreviations used: Con, control; ICAL,
Immunocal®.

SNP is a nitric oxide donor that causes dissipation of the mitochondrial membrane
potential and enhanced generation of mitochondrial ROS in cortical neurons and
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CGNs [143-144]. As expected, nitric oxide species generated by SNP caused overt
apoptotic cell death in CGNs which was significantly mitigated by pre-treatment with
Immunocal® (Fig. 8A). Apoptotic cell counts confirmed that there was significant
neuroprotection in CGNs pre-treated with Immunocal®, decreasing cell apoptosis by
approximately 80% (Fig. 8B). An MTT cell viability assay demonstrated similar
results and showed that mitochondrial viability was also significantly preserved in
Immunocal®-pre-treated cells, compared to CGNs treated with SNP alone (Fig. 8C).

Figure 9. Immunocal® protects CGNs from AlCl3-induced toxicity A. Representative images of
CGNs left untreated (control), treated with AlCl3 (10 μM), or pre-incubated with Immunocal® for
24h before AlCl3 treatment for a further 48h. Panels from left to right, pseudocolored DAPI,
pseudocolored β-tubulin, merged image showing β-tubulin (green), and DAPI (blue). Scale bar,
10 μm. B. Cell survival was quantified for 4 independent experiments as described in A. Results
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are shown as mean +/- SEM, n=4. *** indicates p<.001 compared to control, † indicates p<.05
compared to AlCl3. Abbreviations used: Con, control; ICAL, Immunocal®.

Aluminum is a neurotoxic metal that impairs mitochondrial structure and
function in neural cells exposed in vitro and in vivo [145,146]. AlCl3-induced
toxicity in CGNs was characterized by nuclear condensation and marked
disruption of the microtubule network; these effects were markedly decreased in
CGNs pre-treated with Immunocal® (Fig. 9A). To confirm that this protection
was due to cysteine supplementation, and not metal chelation, we removed the
Immunocal® after the pre-treatment period and washed the CGNs with serumfree media before treating with AlCl3. Under these conditions, we still observed a
significant increase in cell survival compared to CGNs treated with AlCl3 alone
(Fig. 9B).
3.4. Immunocal® prevents caspase-3 cleavage in CHO cells transfected with WT
APP
To explore the role of Immunocal® in a different cell model, we
transiently transfected CHO cells with wild type (WT) APP. We have recently
shown that overexpression of WT APP induces GSH-sensitive opening of the
mitochondrial permeability transition pore and intrinsic apoptosis in CHO cells
[13]. Both control cells transfected with an empty DsRed plasmid, as well as
CHO cells overexpressing DSRed-WT APP that were incubated with
Immunocal® post-transfection, expressed very low levels (10-20%) of active
caspase-3. In contrast, untreated cells overexpressing WT APP showed a marked
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increase in immunoactivity for active caspase-3 to approximately 50% (Fig. 10A).
Quantification of active caspase-3 revealed that there was a significant decrease in
CHO cell apoptosis in Immunocal®-treated cells compared to non-treated CHO
cells overexpressing WT APP (Fig. 10B).

Figure 10. Caspase-3 activation induced by wild type APP overexpression in CHO cells is
decreased with Immunocal® treatment A. Representative images of CHO cells subject to wild
type DsRed-APP overexpression in the absence or presence of Immunocal® incubation. Panels
from left to right, pseudocolored DAPI, active caspase-3 (green), merged image showing active
caspase-3 (green), and DsRed (red). Scale bar, 10 μm. B. Quantification of transfected CHO cells
expressing active caspase-3. Results are shown as mean +/- SEM, n=4. *** indicates p<.001
compared to DsRed, † indicates p<.05 compared to APP. Abbreviations used: APP, amyloid
precursor protein; ICAL, Immunocal®.
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3.5. Immunocal® protects NSC34 motor neuron-like cells from H2O2 and glutamate glycineinduced toxicity

Glutamate excitotoxicity is thought to play a role in ALS, leading to
neuronal damage and apoptosis. NSC34 motor neuron-like cells are used as a
model for studying motor neuron disease; however, cells do not express
functional glutamate receptors until cells are exposed to serum withdrawal for 7
days in culture and allowed to reach a higher level of maturity under these
conditions rather than normal growing conditions. After this point cells become
sensitive to glutamate excitotoxicity, which is an interesting in vitro model for
ALS [147]. We show here that glutamate glycine (1 mM/100 μM) caused
apoptotic cell death in NSC34s after serum withdrawal, which was significantly
mitigated by pre-treatment with Immunocal®. An MTT cell viability assay
demonstrated that mitochondrial viability was preserved in Immunocal®-pretreated cells in a dose-dependent manner, compared to NSC34 cells treated with
glutamate glycine alone (Fig. 11A).

41

Figure 11. Immunocal® protects NSC34 cells from glutamate glycine and H2O2-induced toxicity
A. Cell survival was quantified for 2 independent experiments in NSC34 left untreated (con),
treated with glutamate glycine (1mM/100 μM), or pre-incubated with Immunocal® for 24h
before glutamate glycine treatment for a further 24h. B. Cell survival was quantified for 2
independent experiments in NSC34 left untreated (con), treated with H2O2 (250 μM), or preincubated with Immunocal® for 24h before H2O2 treatment for a further 24h. Results are shown
as mean +/- SEM, n=2. Abbreviations used: Con, control; ICAL, Immunocal®; glu. gly.,
glutamate glycine.

H2O2-mediated cell apoptosis is a classic model of ROS in neuronal
systems, as it generates free radicals that are hallmark in neurodegeneration [148].
As expected, ROS generated by H2O2 caused overt apoptotic cell death in
NSC34s which was significantly mitigated by pre-treatment with Immunocal®.
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An MTT cell viability assay demonstrated that mitochondrial viability was
preserved in Immunocal®-pre-treated cells in a dose-dependent manner,
compared to NSC34 cells treated with H2O2 alone (Fig. 11B).
3.6. Immunocal® delays disease onset but does not extend lifespan in the hSOD1G93A
mouse model of ALS
After finding that Immunocal® provided significant neuroprotection in vitro from
multiple insults, we investigated the effects of Immunocal® supplementation in the
hSOD1G93A mouse model of ALS. Beginning at 60 days-of-age, mice received
Immunocal® ad libitum in drinking water. Although there was no measurable
difference in lifespan (Fig. 12A), Immunocal®-supplemented mice displayed a
significant delay in disease onset of approximately 7 days (7 ±1.1 days) (Fig. 12B).
Mice were visually assessed for deficits in motor function and coordination daily,
and by PaGE hanging wire grip test twice a week. PaGE testing revealed a highly
significant decrease in the rate of decline in grip strength between 100 days and 120
days of age when Immunocal®-treated mice were compared to hSOD1G93A mice that
did not receive supplementation (Fig. 12C). Thus, Immunocal® preserved grip
strength and delayed onset of motor dysfunction in this mouse model of familial ALS.
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Figure 12. Immunocal® delays clinical onset and diminishes the rate of decline in grip
strength in the hSOD1G93A mouse model of ALS A. Median survival is not significantly
different between hSOD1G93A mice receiving Immunocal® ad libitum and untreated mutant mice
(n= 13). B. hSOD1G93A mice receiving Immunocal® ad libitum displayed a delay in disease onset
and clinical decline compared to untreated mutant mice (n=13). Onset curves are significantly
different (p<.001) determined by Gehan-Breslow-Wilcoxon Test. C. PaGE hanging wire test
represented as (mean ± SEM) latency to fall at indicated ages (n=13). *** indicates p<.001
compared to NonTG, ** indicates p<.01 compared to NonTG, † indicates p<.05 compared to
hSOD1G93A mice (one-way ANOVA with a post-hoc Tukey’s test).
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3.7. Immunocal® prevents GSH depletion in whole blood and lumbar spinal cord of
hSOD1G93A mice

Figure 13. HPLC-EC detection reveals whole blood GSH is depleted in the hSOD1G93A mouse
model of ALS and is preserved at NonTG levels in hSOD1G93A mice receiving Immunocal® A.
Mean GSH and GSSG concentrations and GSH/GSSG ratios from the whole blood of end stage
trial animals, n=13. ** indicates p<.01, * indicates p<.05. B. Representative HPLC-EC
chromatograms from the whole blood of end stage animals, peaks of interest include GSH
oxidizing at 600 and 800 mV.

The neuroprotective effects of Immunocal® observed in vitro are largely due to
its capacity to enhance GSH synthesis by providing the key precursors cystine and
cysteine. To investigate this potential mechanism of action in vivo, whole blood and
lumbar spinal cord tissue was collected from end-stage hSOD1G93A mice and analyzed
for reduced GSH and oxidized GSSG using HPLC-ECD. We found that hSOD1G93A
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mice that did not receive supplementation displayed a significant decrease in whole
blood GSH when compared to nontransgenic littermate controls (NonTG). Levels of
GSSG in whole blood did not significantly change; however, the ratio of GSH to
GSSG in whole blood was significantly decreased in hSOD1G93A mice compared to
NonTG controls. Both the decreases in GSH and the reduction in the GSH/GSSG
ratio were prevented in hSOD1G93A mice receiving Immunocal® (Fig. 13A).
Representative HPLC chromatograms from these animals are shown in Figure 13B.
Most interestingly, we found that a similar pattern also existed for GSH levels in
the lumbar spinal cord of study animals. Spinal cord GSH levels were decreased by
approximately 50%, GSSG levels were elevated two-fold, and the ratio of GSH to
GSSG was significantly decreased in hSOD1G93A mice compared to NonTG controls.
Immunocal® treatment prevented these changes in GSH and GSSG and maintained
the GSH/GSSG ratio at a level that was indistinguishable from NonTG controls (Fig.
14A). These results indicate that preservation of whole blood and spinal cord GSH
levels correlates with the beneficial effects of Immunocal® supplementation in the
mutant hSOD1G93A mouse model of ALS. Representative chromatograms from these
animals are displayed in Figure 14B.
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Figure 14. HPLC-EC detection reveals lumbar spinal cord GSH is depleted in the hSOD1G93A
mouse model of ALS and is maintained at NonTG levels in hSOD1G93A mice receiving
Immunocal® A. Mean GSH and GSSG concentrations and GSH/GSSG ratios from the lumbar
spinal cord of end stage trial animals n=17. * indicates p<.05. B. Representative HPLC-EC
chromatograms from the lumbar spinal cord of end stage animals, peaks of interest include GSH
and GSSG oxidizing at 600 mV.

3.8. Strawberry anthocyanin extract delays disease onset and extends lifespan in the
hSOD1G93A mouse model of ALS
In addition to our studies with Immunocal®, we investigated a strawberry
anthocyanin extract (SAE) for its efficacy in the SOD1G93A mouse. After isolating the
extract, we confirmed that the major anthocyanin in the final isolate was callistephin
at 9.3 min retention time using HPLC-UV analysis (Fig.15). We next began oral
dosing with a 5% solution of SAE twice daily in the hSOD1G93A mouse model of
ALS.
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Figure 15. HPLC-UV identification of major anthocyanin in strawberry extract. A.
Chromatogram of callistephin (Pelargonidin-3-O-glucoside) standard. B. Chromatogram of
strawberry anthocyanin extract.

We saw a significant delay in disease onset, and a significant increase in
survival in the hSOD1G93A mice receiving SAE (Fig. 16A&B). Additionally, there
was a significant retention in motor function in the hSOD1G93A mice receiving
SAE (Fig. 16C). The antioxidant properties of these nutraceuticals, particularly at
the level of the mitochondria, appear to underlie their neuroprotective effects;
however, further investigation into the mechanism behind this neuroprotection is
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necessary in further exploration of these compounds as natural therapies for
neurodegenerative disease.

Figure 16. SAE delays clinical onset, increases survival, and diminishes the rate of decline
in grip strength in the hSOD1G93A mouse model of ALS A. Median survival is different
between hSOD1G93A mice receiving Immunocal® ad libitum and untreated mutant mice (n= 2). B.
hSOD1G93A mice receiving Immunocal® ad libitum displayed a delay in disease onset and clinical
decline compared to untreated mutant mice (n=2). C. PaGE hanging wire test represented as
(mean ± SEM) latency to fall at indicated ages (n=2). *** indicates p<.001 compared to NonTG,
** indicates p<.01 compared to NonTG, † indicates p<.05 compared to hSOD1G93A mice, ††
indicates p<.01 compared to hSOD1G93A mice, ††† indicates p<.001 compared to hSOD1G93A
mice (one-way ANOVA with a post-hoc Tukey’s test).
49

Chapter 4. Discussion
Here, we show that Immunocal® elevates cellular GSH levels and
provides neuroprotection in vitro. We also show that it delays disease onset,
attenuates decline in motor function, and sustains whole blood and spinal cord
GSH at NonTG levels in the hSOD1G93A mouse model of ALS. However,
previous research using nutraceutical antioxidants in neurodegenerative disease
has translated to relatively nominal clinical efficacy. For instance, vitamin E
initially received a great deal of attention for its antioxidant activity in cellular
and murine models of ALS, however its clinical translation was discouraging
[149]. Yet there is a great deal of research that points to good nutrition and
nutritional supplements as being clinically beneficial against neurodegeneration,
arguing that there is promise within this field[150]. Nevertheless, there should be
a greater selectivity of the nutritional supplements that make it to the clinic.
Studies that point to a readily available and non-prescription relief for a
disease as devastating as ALS may be an appealing alternative for affected
patients. For this reason, among others, we looked to a nutraceutical antioxidant
for its neuroprotective activity in these disease models. Immunocal® was a
unique option because of its undenatured conformation and high cystine
concentration, as well as its potential to mitigate some aspects of ALS that are
hallmark in the disease [55]. It has been shown that ALS patients who receive
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whey protein supplement present weight gain and increased body mass compared
to control group patients, suggesting that Immunocal® may have this benefit in
addition to its effects on the available GSH pool [151].
Although researchers may disagree on the correct path to potential
therapeutics, there is an understanding in the field that neurodegenerative
diseases, such as ALS, have underlying mitochondrial dysfunction. Therefore,
there is an emerging class of treatment modalities that target mitochondrial
function as a potential therapy. For instance, dexpramipexole, a drug that is
currently in phase III clinical trials for ALS is a mitochondrial modulator, and has
had encouraging results in phase I and II trials. It is suspected to preserve
mitochondrial function through its antioxidant activity, inhibition of pro-apoptotic
proteins, and preserving mitochondrial structure [152, 153]. Effective treatments
that target mitochondrial function such as dexpramipexole suggest that
mitochondrial dysfunction is an underlying aspect of ALS, and therapies that
target mitochondrial antioxidant defenses similarly hold promise in this field.
Mitochondrial GSH depletion is associated with increased apoptosis in
NSC34 cells stably expressing the hSOD1G93A mutation [51]. Additionally, GSH
depletion in the hSOD1G93A mouse is correlated with increased age-dependent
motor degeneration [154]. Therefore, increasing the available cellular and
mitochondrial GSH pool, and decreasing oxidative stress by promoting
endogenous cellular defenses is an appealing treatment modality. As
aforementioned, cysteine supplementation and providing the limiting precursor
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for GSH synthesis holds promise for therapy in various neurodegenerative
diseases, including ALS [155]. In accordance with these data, Immunocal®
treatment and modulation of the GSH pool is a very promising therapy for ALS,
particularly at the level of the mitochondria.
It is posited that the best exogenous precursor for GSH is the amino acid
cystine [156]. Cystine is transported across the astroglial cell membrane in
exchange for glutamate by the X-c transport system in astroglial cells, and it is
broken down into cysteine and used in GSH biosynthesis [157]. Although this is
not the only mechanism behind the anti-apoptotic role of Immunocal®, this is an
interesting aspect of the supplement and further investigation is necessary into
this potential neuroprotective role.
In this study, we also showed that strawberry anthocyanins provided
neuroprotection in the hSOD1G93A mice. These preliminary data are very
promising and suggest that there may indeed be a role for these nutraceuticals in
the clinic after further investigation into their mechanism of action. In addition to
our findings, several recent in vivo studies have exhibited exciting results using
anthocyanins, suggesting that these novel nutraceuticals could be beneficial in a
clinical setting for neurodegenerative diseases. A central aim of these other
studies was to examine the therapeutic potential of anthocyanins in the treatment
of specific neurodegenerative diseases, specifically using animal models of PD. In
the MPTP mouse, a neurotoxin model widely used to test potential therapeutic
options for PD, anthocyanin treatment preserved dopamine neurons in the
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substantia nigra pars compacta and dopaminergic innervation of the striatum
[114]. Anthocyanins have also exhibited neuroprotection in rats subjected to
unilateral striatal lesioning with 6-OHDA, reinforcing their potential in this
particular neurodegenerative disease [158]. Anthocyanins have also been shown
to have neuroprotective effects in in vivo models of acute neuronal injury such as
middle cerebral artery occlusion and reperfusion in rats [159].
Anthocyanins have also been examined in models of aging, as research
suggests that oxidative stress plays a large role in the etiology of aging. Recent
studies investigating anthocyanins have revealed other potential benefits of these
nutraceuticals. Anthocyanins appear to diminish age-related oxidative stress
[106,160]. Treatment with anthocyanins significantly attenuated cytosolic
cytochrome c release, and promoted neuronal survival in a model of D-galactoseinduced brain aging in old mice [106]. Finally, in a recent clinical study,
consumption of wild blueberry juice for 12 weeks enhanced memory performance
in older adults with early symptoms of dementia [160]. These data are suggestive
of a possible therapeutic role for anthocyanins in age-associated cognitive
impairment.
An important element of anthocyanin treatment is the cell type-specific
effects of these compounds exhibited both in vitro and in vivo. As they act in a
pro-apoptotic fashion in cancer cells, and as anti-apoptotic agents in neurons, it is
clear that their effects on cell physiology are complex.
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Anthocyanins affect many different signaling pathways in different cell
systems. They exhibit anti-proliferative, anti-inflammatory, and pro-apoptotic
effects in cancer cells, supportive of their use as chemotherapeutic agents. They
also exhibit strong antioxidant and anti-apoptotic effects in neuronal injury
models, which provides evidence toward the potential of anthocyanins as a novel
treatment for neurodegeneration. In vivo studies in animal models of
neurodegeneration involving anthocyanins have delivered promising results that
may lean towards their clinical development in neurodegenerative diseases.
Studies in human subjects are limited, but are also promising for this treatment
modality. These novel nutraceuticals displayed promising effects in preliminary
clinical studies of memory impairment in older adults, again suggesting the
potential benefit of developing anthocyanins for the treatment of
neurodegenerative diseases [160]. Though the data in human models are limited
and preliminary, they provide a basis for more comprehensive human trials of
anthocyanins as neuroprotective agents. Seeing the clinical potential of
anthocyanins, recent studies are directed towards delivery methods of these
anthocyanins in vivo, even looking toward slow anthocyanin-releasing implants
for a novel delivery method in disease prevention and treatment.
The unique properties of anthocyanins may be extremely beneficial for the
clinical treatment of chronic human diseases, as diverse as cancer and
neurodegeneration. Future development of these nutraceuticals as neuroprotective
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agents will one day hopefully lead to their use in a clinical setting for the
treatment of neurodegenerative diseases as well as highly invasive cancers.
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Chapter 5: Conclusions and future directions
Experiments in vitro have convincingly demonstrated that cystine
supplementation via Immunocal® may be promising against an array of
neurodegenerative disease-relevant insults. Here, we show that Immunocal®
protects CGNs against the Bcl-2 inhibitor, HA14-1, and that this effect is
diminished when CGNs are co-incubated with BSO, which is a de novo GSH
synthesis inhibitor. Futhermore, we show that Immunocal® protects CGNs from
CuCl2 , AlCl3, and SNP-induced toxicity. In CHO cells that are transiently
transfected with wild type APP, Immunocal® decreases active caspase-3
expression. Moreover, in NSC34 motor neuron cells we saw that Imunocal®
increased cell viability in a dose-dependent manner in cells treated with either
H2O2 or glutamate glycine. These data are promising in vitro, and were
encouraging enough to study the effects of Immunocal® in the hSOD1G93A mouse
model of ALS. We found that Immunocal® administered orally ad libitum
reduced age-associated decline in muscle function, as measured by the PaGE grip
endurance test. We also show that Immunocal® increased healthspan by delaying
disease onset in mutant mice. Finally, we show that Immunocal® prevented
whole blood and spinal cord GSH depletion in the hSOD1G93A mice, and
maintained GSH at NonTG levels in the mice receiving supplementation.
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After isolating an anthocyanin-enriched fraction from freeze-dried
strawberries (SAE) and testing their efficacy in the hSOD1G93A mouse model of
ALS, we show a significant neuroprotective effect. SAE significantly delayed
disease onset and extended survival in the hSOD1G93A mice receiving the extract
orally. We also show a significant retention in motor function, as measured by the
PaGE grip endurance test. These data are preliminary, and further investigation
into the mechanism of action is necessary to further develop these compounds for
their neuroprotective effects. These collective data suggest that nutraceutical
intervention holds potential in neuroscience, and that compounds such as
Immunocal® and SAE deserve further investigation in models of
neurodegeneration.

Figure 17. Schematic of possible clinical synergy leading to neuroprotection.

Our future studies involving these compounds will model a clinical
synergy approach to pharmacologically moderate cell death. For instance, if we
combine Immunocal® with the glutamate inhibitor, Riluzole, we should see an
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increase in survival in the hSOD1G93A mouse, as these compounds will affect
different aspects of neurodegeneration that are hallmark in these diseases (Fig.
16.) Furthermore, if we couple these compounds with an Nrf2-inducer, which will
increase GSH synthesis, we will theoretically see an increase in the resulting
neuroprotection. Future studies with Immunocal® are promising and they should
give rise to a novel approach using nutraceuticals to enhance pharmacological
intervention in ALS and other neurodegenerative disorders.
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